Skip to content

MicroRNA profiles in blood and urine in lung cancer: a pilot study

MicroRNA profiles in blood and urine in lung cancer: a pilot study - MicroRNA profiles in blood and urine in lung cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON46585
Enrollment
100
Registered
2018-05-03
Start date
2018-07-18
Completion date
Unknown
Last updated
2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lungcancer

Interventions

None listed

Sponsors

Universiteit Twente
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: maximal 75 patients with a suspicion of lung cancer (in order to obtain 25 patients with lungcancer stage 3 / 4 and 25 patients with a negative diagnosis) - between 45-80 years of age

Exclusion criteria

Exclusion criteria: Patients; known other than lung cancer malignity, urinary tract infection Controls: known other than lung cancer malignity, no suspicion of lung cancer malignicy, pneumonia, urinary tract infection

Design outcomes

Primary

MeasureTime frame
The main study parameters are microRNA sequencing data (read-counts per microRNA) derived from next generation sequencing of the small RNA fractions of blood and urine. The sequencing data will be correlated to clinical parameters: diagnosed with lung cancer (CT, histopathology), suspected of having lung cancer but not diagnosed (CT, possibly histopathology), not-suspected of lung cancer or any other disease.

Secondary

MeasureTime frame
Measurements of volatile organic compounds (VOCs) resulting from the electronic nose technology. With the primary outcomes and the secondary outcomes a predictive model will be developed to predict the probability for having lung cancer.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)